John P. Hennessey, Jr.

Dr. Hennessey joined NovaDigm Therapeutics as Vice President, Research & Development in 2009. He has over twenty years of vaccine and biologics development experience, with a primary focus on the chemistry, manufacturing and control (CMC) aspects of product development. Much of his past efforts have been focused on process, analytical and formulation development of vaccine products in preclinical as well as early- and late-stage clinical development. He joined Merck & Co., Inc. in 1989 and became a key leader for development, technology transfer and licensure of five new vaccines as well as three second generation vaccines. Additionally, he was integral to the preclinical and clinical development of a wide variety of vaccine and biologics programs and provided post-licensure technical support for several commercial vaccines. He has co-authored over 30 peer-reviewed articles, many related specifically to vaccine development activities, and three book chapters, is a co-inventor on eight patents and has given invited presentations at over 35 national and international conferences.